238 veterinary surgeons responded to the survey which found that 52.3% of practices reported that they do not have all the veterinary surgeons they need, with the average shortfall being 21.6% or approximately 1/5th of the workforce.
28% reported that this lack of vets meant that they are unable to cover their OOH without unacceptable levels of overtime.
88% of practices had tried to recruit in the past 12 months, 31% of which had failed to find a candidate at the time of the survey.
SPVS carried out a similar survey in 2015 and a comparison between the two showed a worsening situation with only 22% of practices finding a new recruit within three months compared to over 30% two years ago. 90% of respondents also felt the recruitment situation had worsened since four years ago.
An unwillingness to do OOH and dissatisfaction with working hours was cited as the most common reason for candidates not accepting a position, mirroring the results of a survey carried out by VetSurgeon Jobs in 2016. This, combined with most respondents saying that personally they planned to reduce their working hours suggests that the crisis can only deepen and that to succeed in recruitment, employers will have to consider more flexible working.
Brian Faulkner, SPVS President said: "This survey provides valuable evidence to support the profession as they work with government and the colleges to try and counter this crisis in recruitment which threatens to get worse with Brexit. If not tackled it will become increasingly difficult for vets to provide a satisfactory 24 hour health service for the UK’s pets, horses and farm animals."
VetSurgeon.org Editor, Arlo Guthrie said: "This is precisely why recruitment adverts on VetSurgeon.org Jobs run for two months rather than the one month typically offered on other websites. In these difficult times, it is also important to try and use every trick in the book to spread the word about your job, and present it in a way that really stands out. On that score, we're working on some new features designed to help good employers stand out from the crowd. Watch this space."
The full survey is available on the SPVS website at: www.spvs.org.uk
David, who is Head of Clinical Intelligence at Vets Now, came in eighth place with 1,756 votes in this year’s RCVS Council elections.
The place was originally offered to Dr Tom Witte, who came in seventh place. However, due to a change in personal circumstances, he decided not to accept.
Professor Stephen May, RCVS President, said: "The loss of such a young, talented and respected Council member as Sarah has been difficult to come to terms with and she is greatly missed by her fellow Council members and others amongst the profession.
"It is also important to recognise that the New Year will bring us fresh challenges and opportunities and we will face them best with a full complement of Council members. Therefore, I am delighted that David will be joining Council from January and is able to attend his first Council meeting, which will be held in committee, with us on Thursday 18 January.
"The circumstances under which David will be joining us have been extremely sad, but I am sure he will be an excellent addition to our team and I look forward to working with him."
More information about David Leicester, including his candidate biography and manifesto, can be found in the Council election booklet sent out earlier this year and available to download from www.rcvs.org.uk/publications. A video of David talking about what he would bring to RCVS Council can also be found on the College’s YouTube channel: www.youtube.com/rcvsvideos
Research amongst veterinary surgeons by Janssen Animal Health, maker of Cavalesse oral and Cavalesse topical, has revealed that owners could be doing more harm than good when it comes to managing sweet itch in their horses.
92% of vets questioned are aware that people follow old wives' tales by administering lotions and potions such as garlic and olive oil to ward off flies during the summer sweet itch season, when garlic actually has the opposite effect of attracting them.
According to Janssen, it is thought that only a quarter of horse owners are aware that it is important to carry out preventative measures before the start of the midge season to help alleviate sweet itch. 14% of people are thought to go to their vet for advice on sweet itch, while 30% seek help from their country store or tack shop, 27% search for information on websites and 26% ask other horse owners for guidance. This is despite the fact that 92% of those questioned believe that sweet itch would clear up quicker if people sought advice from their veterinary surgeon.
Nicki Glen, marketing manager at Janssen Animal Health said: "Sweet itch can be an incredibly difficult and frustrating condition to manage, however horse owners do not tend to seek advice from their vets. It is therefore important to educate horse owners while you are on yard visits with pro-active advice on the condition for the long-term health and welfare of horses."
Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including nicotinamide. Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump. Janssen says the supplement helps horses maintain a healthy skin and promotes normal immune function in horses prone to summer allergies.
Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution. The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.
For further information on Cavalesse and Cavalesse Topical please contact your Janssen Animal Health account manager or phone 01494 567555.
Vets Now Ltd, the provider of out-of-hours emergency vet care has announced the acquisition of Salus Quality Partnerships (QP), a Health and Safety service provider to the veterinary profession in the UK.
Vets Now says this acquisition will extend the range of its services aimed at improving the quality of life within the profession and supporting practices to run more efficiently.
Vets Now currently runs 50 emergency clinics throughout the country including two referral hospitals in Scotland and the South West of England. In recent years Vets Now has extended its offering to the profession to include business services aimed at supporting vet practices. These services include Lifelearn (Client Education & Compliance), Staff Training Services, RCVS Practice Standards support and Practice Web services.
Salus QP, which has been running for over 18 years, offers veterinary practices information and services to help them comply with Health and Safety legislation and an anaesthetic monitoring service.
Richard Dixon, Founder of Vets Now said: "Our core purpose at Vets Now has always been to improve the lives of vets and pets, and the recent addition of Salus QP will help to do exactly that. The Salus QP team, led by Mark Enright and Alison Clark, have extensive knowledge in their field and crucially they fully understand the issues as they specifically apply to veterinary practices. With Salus QP our aim is to keep it simple and practical, helping practices fulfil their obligations without letting the Health and Safety tail wag the practice dog. I am very much looking forward to working with both Mark and Alison in the future as we take a fresh and common sense approach to Health and Safety in our profession."
Mark Enright said: "Salus QP and Vets Now both share a strong commitment to the veterinary profession and I truly believe that together we will be greater than the sum of our parts. I look forward to a future of innovations and benefits for all, and to continue to form quality partnerships within the veterinary profession."
The practice is one of few in the UK to use radioactive iodine (RAI) therapy, which, it says, has an average, a 95% success rate in treating cats with hyperthyroidism.
Stephanie Lalor MRCVS (pictured right), an RCVS Specialist in Feline Medicine at Willows said: "The new therapy is non-invasive and is the gold standard of treatment for cats with hyperthyroidism. It is safe and highly effective and a single injection can be curative. Patients do need to be screened for their suitability and ideally they are treated with medical therapy prior to the RAI.
"Due to the radioactive nature of the treatment, patients must stay with us for 15 days after the injection. Our patients stay in luxury cat condos during their hospitalisation and their day-to-day care is over-seen by our lead radioactive iodine nurse, Vicky Maund."
The new unit is part of a £1 million investment in Willows which includes a dedicated operating theatre for minimally invasive procedures, a range of specialist treatment rooms and more than 40 new kennels.
Toby Gemmill, clinical director at Willows, said: "We are already extremely well placed to offer a wide variety of specialist treatments and this extension has provided us with the space to expand our services further. The new radioactive iodine unit is very exciting and allows us to build on our gold level cat-friendly clinic status."
For more information, visit www.willows.uk.net.
Dr Neil Bryant from the AHT, who is leading the research, said: "EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world. It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease."
As a viral infection, EHV can cause respiratory disease, abortion or fatal illness in new born foals and neurological disease in adult horses, with signs ranging from slight wobbliness through to complete paralysis. The disease can strike any horse at any time because the virus, like other herpesviruses (such as the cold sore virus in humans), becomes dormant within most horses early in their life. It then re-emerges when the animal is later stressed such as when transported or mixed with new horses. A seemingly healthy pregnant mare may suddenly, and without warning, abort her unborn foal or may show signs of respiratory disease including mild fever, coughing and discharge from the nose. A horse which appears fit and well may suddenly show abnormalities when walking and within hours may be unable to stand.
Despite the potential severity and impact of outbreaks, there is still no vaccine that is licensed to protect against the neurological form of the disease and abortions still occur in highly vaccinated horse populations. The AHT says protection afforded by existing vaccines currently in use is sub-optimal, something that was highlighted by the 2016 abortion storm in Hertfordshire in fully vaccinated animals.
Neil added: "We have become aware of a pressing need for progress towards a new and improved EHV-1 vaccine. Just last month, the AHT was again called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in premises in Yorkshire and Suffolk."
To that end, the charity has now established the Equine Industries EHV Vaccine Steering Group. Chaired by Professor Joe Brownlie of the RVC, the steering group includes world-renowned experts on both human and equine herpes viruses from a number of research establishments, who have concluded that the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.
After securing funding from a large number of organisations, including the Alborada Trust, EBM Charitable Trust, Horserace Betting Levy Board and the Racing Foundation, Paul Mellon Estate, Thompson Family Charitable Trust, Coolmore Ireland, Newsells Park Stud, Thoroughbred Breeders’ Association and Juddmonte Farms, the AHT has begun its five-year research programme.
Neil added: "We’re at the beginning of a very exciting and potentially ground-breaking vaccine development. Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs. We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1."
Professor Steve Dean MRCVS has been elected as the 14th Chairman of the Kennel Club. He is the first veterinary surgeon to hold the post.
Professor Dean has been a Member of the Kennel Club since 1992 and has been a member of the General Committee since 2005. He has served on the Crufts and Finance & General Purposes Sub-Committees for the past two years and previously spent four years on the Disciplinary Sub Committee.
Professor Dean said: "I am honoured to be elected as Chairman of the Kennel Club and to be given the opportunity to help improve the lives of dogs by ensuring that they live healthily and happily with responsible owners.
"I am aware of the scale of some of the challenges that we face but am excited about the opportunities that exist to help us make a real difference for dogs. I look forward to supporting and working with the millions of responsible dog breeders and owners that there are in this country, and to standing shoulder to shoulder with vets and other individuals and organisations, who are dedicated to improving the health and welfare of dogs."
Professor Dean, who turns 60 in August, is currently the Senior Veterinary Surgeon at Crufts each year. He is a breeder, exhibitor and judge of Border Terriers and has been involved in the breed for 30 years. He is currently Chairman of the Southern Border Terrier Club as well as the overall breed health co-ordinator for all seven breed clubs. He is also President of Windsor Dog Show Society.
Away from the world of dogs, Professor Dean is a keen reader and gardener and is an avid supporter of rowing, treasuring his Henley Regatta medal equally to his achievements in the show ring.
The research found that 93% of practices have a washing machine on site, but two thirds of those use a domestic machine rather than a commercial one. 69% of staff also take their uniform home to wash in a domestic machine.
Only commercial machines conform to the WRAS regulations, with thermal disinfection capabilities to minimise the risk of cross infection.
The survey also provided an argument for using a robust commercial machine able to cope with high levels of usage and the variety of materials needing to be cleaned: 83% of practices said they use their machines more than once a day and listed bedding, drapes and gowns as the most common materials that need to be cleaned regularly.
Les Marshall, Sales & Marketing Director at Miele Professional, said: "Our research shows that veterinary staff realise the importance of hygiene when cleaning their laundry. At Miele Professional we understand that preventing infection is key. When caring for animals who need medical care, reliable and effective equipment that can wash items ranging from bedding to gowns to reusable bandages is essential.
"As a leading supplier to the care and hospital sectors, all our machines are tested and approved to Water Regulatory Advisory Scheme (WRAS) category 5 for mains connection in any high-risk establishment."
The company says that in addition to meeting WRAS category 5 requirements, it's machines:
Miele Professional is exhibiting at the London Vet Show and will be holding a seminar on 'Controlling the risk of infection with a commercial laundry system' in the Business Theatre on 18 November, 12-12.50pm.
The seminar will explore the benefits of using a commercial laundry over a domestic machine, best practice around thermal disinfection and why it’s vital for veterinary practices to meet WRAS category 5 requirements.
For more information visit www.miele.co.uk.
Reference
95 respondents were surveyed online in June 2016
Inigo’s abstract entitled “Predictive value of cardiac remodelling on survival in dogs with persistent atrial standstill – the UK perspective” sought to determine the survival of dogs in the United Kingdom with persistent atrial standstill (PAS) after pacemaker implantation and the prognostic value of cardiac remodelling. The Congress Programme Committee were impressed by Inigo’s innovative presentation, praising the planning and execution of the multi-centre project.
Ditte’s presentation was entitled “Evaluation of a point-of-care dot Enzyme-Linked Immunosorbent Assay to detect antibodies against canine parvovirus, distemper virus and adenovirus before revaccination”.
Her study described the findings of a prospective non-inferiority study of a point-of-care semi-quantitative titer test performed on canine serum samples and compared to gold standard analysis. Sensitivity, specificity, positive and negative predictive values of the point-of-care titer test were determined for the gold standard titer cut-offs for canine adenovirus, canine distemper virus and canine parvovirus. Ditte was commended by the Congress Programme Committee for the quality of presentation as well as the practical and clinically applicable findings of the study.
The BSAVA Congress Clinical Abstracts, including the winners’ abstracts, are now available to view in the BSAVA Library here: https://www.bsavalibrary.com/content/book/10.22233/9781913859039.
The plans developed by the Animal and Plant Health Agency (APHA), an agency of the Department for Environment, Food & Rural Affairs (DEFRA), involved the creation of a new role of Certification Support Officers (CSOs), non-veterinarians who would support the work of Official Veterinarians (OVs) in the signing of export health certificates for products of animal origin such as meat, dairy, processed products and animal by-products.
The proposals for the creation of CSOs by APHA has arisen due to concerns about the growth of exports in recent years and the potential for an up to 300% increase in products requiring OV certification if the UK has to certify exports of products of animal origin to the EU once the UK leaves the EU. Under APHA’s plans CSOs will work under the direction of veterinary surgeons and support their certification work (for example, verifying temperature checks), although the final certification will always need to be signed by OVs. The role will not involve certification relating to live animals or germinal products.
At the RCVS Council meeting on Thursday 1 November 2018 Council members agreed to facilitate APHA’s proposals and to make changes to the RCVS requirements so as to allow CSOs to support OVs in their certification work.
Amanda Boag, RCVS President, said: "As we have stated in our recent statement on ‘no-deal’ Brexit, it has been estimated that there would be 325% increase in veterinary certification requirements if the UK leaves the EU without a deal, and with these proposals Defra and APHA are preparing for this by increasing the support available for Official Veterinarians. Furthermore the proposal is in line with the concept of a vet-led team, with veterinary surgeons focusing on tasks only vets can do, whilst delegating some tasks to suitably trained and quality-assured members of our teams.
"We appreciate that there were some concerns over the level of education and training required by CSOs and are glad that the APHA has accommodated those views by increasing the level of education to three A-Levels (or equivalent in Scotland) and clarifying the nature of the training required by CSOs.
"By signalling its support for the proposals, RCVS Council has been assured that the integrity and value of the veterinary signature will be upheld and we are glad that we can play a key role in helping the veterinary profession prepare the UK for leaving the EU."
The RCVS position statement on the potential impact of a ‘no-deal’ Brexit scenario is available at www.rcvs.org.uk/brexit
The 'Room For Rabbits' campaign follows research in which 38% of vets said they think rabbits’ environment is the most neglected welfare need1, with over a quarter of the UK’s rabbits being kept in inadequate housing conditions, and almost half of them living alone2.
The RAW survey also found that 90% of vets believe that rabbits’ welfare in the UK is improving3.
Room for Rabbits will throw a spotlight on rabbits’ environment, with a variety of initiatives during RAW including vet blogs and videos on how to adapt bunnies’ housing for all seasons, boredom buster ideas, a competition to encourage owners to create a RAW ‘gold standard’ environment, and downloadable packs containing resources for practices to create their own RAW campaigns.
Holly Castle, Senior Brand Manager at Burgess Pet Care, RAAG member and organisers of RAW, said: “We are delighted that RAW continues to have a positive impact, with our survey showing that 90% of vets believe that the welfare of the UK’s rabbits is improving - but there is always more than we can do.
“Since the previous RAW campaign, we have successfully launched RAAG, which recognises that the welfare of these wonderful creatures needs to be high on the agenda year-round.
"By bringing together the expertise of the RAW partners, RAAG is focused on encouraging everyone involved with rabbits to support the first Good Practice Code for rabbits’ welfare in England to ensure it becomes enshrined in law.
"One of the ways to achieve this is through initiatives like RAW, which is the UK’s largest welfare campaign of its kind.
“We recognise that vets’ practices were really stretched last year due to the Covid-19 pandemic, which meant it was difficult to support campaigns like RAW.
"However, following a surge in demand for rabbit ownership in the UK during the past two years, it is vitally important that we educate more owners than ever before and continue to help improve rabbits’ welfare."
“The veterinary community plays a hugely important role in ensuring that owners have access to the right information, and we are urging practices to throw their support behind this year’s RAW to ensure that we reach as many owners as possible.
Professor Ian Ramsey, Past President of the BSAVA, which endorses RAW, said: "The BSAVA is once again delighted to support RAW and the theme of this year’s campaign.
"Rabbits remain one of the most misunderstood pets in the UK, but we are confident that vets across the UK will again show their support for this important campaign to improve the lives of pet rabbits.”
The RAAG is encouraging vets’ practices to sign up to receive updates about RAW at https://www.rabbitawarenessactiongroup.co.uk/raw-pack-reminder/.
Downloadable RAW vet packs will also be available from 6th June.
It is hoped the survey will capture the experiences vets have had reporting ADRs, as well as identifying barriers to the current process which could be used to improve the ease with which ADRs are reported in the future.
PhD student Heather Davies (pictured right), who is leading the research project, said: "The survey is an important opportunity to gain insights into the issues that vets face when dealing with ADRs.
"We want to make the process easier in order to improve the safety of veterinary medicines, and ultimately, we need the help of professionals on the front line in order to do that."
She added: "The survey is relatively short and can be completed anonymously.
"We’re really keen to gather as many of your experiences as possible so we’d like to encourage veterinary professionals to complete it."
The research is being carried out as part of a PhD project funded by the Veterinary Medicines Directorate (VMD) in collaboration with the Small Animal Veterinary Surveillance Network (SAVSNET), based at the university.
The survey is now open and you can take part here: https://liverpool.onlinesurveys.ac.uk/adrs-vet
Any questions about the survey can be addressed directly to the researchers: Heather Davies (PhD student): H.H.Davies@liverpool.ac.uk and/or Dr David Killick (Supervisor): David.Killick@liverpool.ac.uk.
Virbac points to how the pandemic has caused a fundamental shift in consumer shopping habits, with e-commerce accounting for more than 30% of retail sales in the UK in 2020 for the first time1.
Alongside the increase in online sales has come an expectation by consumers that all companies should provide a reliable digital service, with 70% saying that they will continue to buy essential goods online post-pandemic2.
At the same time, sales of pet food in the majority of veterinary practices have been hit by the need for social distancing.
Through the new model, when pet owners buy Virbac's low-carb, high protein Veterinary HPM dog and cat food from the company's new web store for home delivery, a commission is paid to the practice.
Remi Mandray, Product Manager at Virbac said: "It’s a win-win for our practices and their clients, who can take advantage of this convenient option to have their pet food delivered to their home, whilst providing the practice with a protected and rewarding business model".
For more information, contact your Virbac Territory Manager.
References
To use the service, you order recycling boxes to suite your needs, and then place them where it will be most convenient for staff to throw the rubbish in.
Once full, you send the box back to TerraCycle via UPS.
It is then saved from incineration or landfills and recycled by TerraCycle.
Once collected, products and packaging are sorted and separated by material composition.
The separated items are then cleaned, shredded, and made into new recycled products such as outdoor furniture and decking, playgrounds, benches, or watering cans.
Hannah James, Head of Environment, Social & Governance at VetPartners said: “We started using the Zero Waste Boxes at our practices during the pandemic to recycle the large volumes of PPE being used, and they were instantly popular with practice teams.
"We’re now recycling plastic packaging, pet food packaging and medicine blister packs through TerraCycle as well, and since 2020 we’ve saved over 14 tonnes of waste from landfill and incineration.
"The Zero Waste Boxes are an important feature of our sustainability strategy, providing a solution for much of the waste generated by veterinary practice that isn’t hazardous and yet isn’t widely accepted for recycling.”
www.vetcycle.co.uk
Ceva Animal Health has extended its Meloxidyl dogs and cats’ range with the launch of a new 5ml Meloxidyl oral suspension for cats.
The company says the new bottle size will provide more prescription options for veterinary practices currently stocking 15ml bottles and is a perfect post-surgery size to send patients home with. The bottles are also clear brown in colour; designed to make it easier for cat owners to see how much liquid is left in each bottle.
Meloxidyl oral suspension for cats contains meloxicam for the alleviation of pain and inflammation. It is licensed for the treatment of musculo-skeletal disorders and the alleviation of post-operative pain.
Rob McLintock, business unit manager at Ceva Animal Health said: "The new 5ml Meloxidyl oral suspension for cats’ bottle will provide veterinary practices with more prescription options for the management and alleviation of pain and inflammation in cats."
To support the launch of the new 5ml Meloxidyl presentation, Ceva is running a competition to win one of five BSAVA Manuals of Anaesthesia and Analgesia by answering one question: ‘How many millilitres are in the new Meloxidyl cat bottle’?
To enter the competition, email analgesics-group@ceva.com. Include ‘Meloxidyl competition’ in the subject line and contact details and the answer to the question in the main body of the email.
For further information on Ceva’s analgesic product range, contact your local Ceva territory manager, email analgesics-group@ceva.com or call 01494 781510.
The new tool uses aggregated data from Banfield Pet Hospital medical records to identify whether a dog has a high, medium, or low risk of having PD based on the breed size1,2,3,4,5, age, and body condition the owner has stated3,4.
It also makes oral care recommendations based on the dog's history (e.g., diet, previous extractions, halitosis), clinical signs (e.g., bleeding gums) and current dental routine (e.g., tooth brushing).
Global Petcare R&D VP at Mars Pet Nutrition, Dr. Elise Malandain said: “This new risk assessment tool will help indicate to pet owners what level of risk their pet is at for developing this disease to help inform conversations with veterinary professionals about prevention or treatment.”
https://www.uk.pedigree.com/gum-disease-risk-checker
Virbac Animal Health has launched CaniLeish, the first vaccine for canine leishmaniosis in the European Union.
Leishmaniosis is a vector-borne parasitic disease caused by infection with protozoa of the genus Leishmania (L infantum in Europe). Leishmaniosis is transmitted by the bite of infected sandflies. In south-western Europe 2.5 million dogs are believed to be infected1,2 with the parasite and the disease is spreading northwards,3 as more people travel with their dogs or import infected animals from endemic areas.4 So far preventative methods have been limited to reducing the habitat of sandflies, minimising the physical contact of dogs with sandflies and using insecticides on dogs (sprays, spot-ons, repellent-collars, etc).
According to Virbac, CaniLeish's ability to protect dogs was demonstrated in an experimental challenge study, where the benefit of vaccination was still evident after one year.5 In an extreme condition natural challenge trial lasting two years under environmental conditions rarely encountered in reality, 93% of dogs vaccinated with CaniLeish did not develop symptomatic leishmaniosis. CaniLeish provides a fourfold reduction in the risk of developing this fatal disease. 6 Its safety profile has been shown in laboratory testing and field trials.7 In addition, Virbac says it contains no whole parasites that could be virulent in any host.
David McGahie BVMS Bsc (VetSci) MRCVS, Medical Department Manager at Virbac SA, said: "The development of this vaccine is a key milestone in the battle against this challenging disease which is a major problem in many regions of the world. Although in the past it was considered a rather exotic disease here in the UK, the advent of the Pet Travel Scheme means it has become increasingly important as a problem for dogs which regularly travel abroad to endemic regions."
CaniLeish can be given to dogs as young as six months of age: the primary course consists of three injections given over six weeks. Dogs should be re-vaccinated annually, with a single dose administered one year after the third injection and annually thereafter.
References:
SPVS/VPMA Congress, which is supported by Boehringer and Citation, will be opened this year by Benjamin Mee, motivational speaker, journalist and the man behind the bestselling book and Hollywood blockbuster "We Bought A Zoo".
Other highlights in the CPD programme include:
The exhibition offers a range of suppliers with advice on marketing, management and business development.
For this year’s President's banquet the theme will be a touch of Moulin Rouge, with high energy festival and party band, RPJ, headed by Rick Parfitt Jnr. Congress will start on Thursday with a Congress Cabaret night, featuring Edinburgh Fringe regulars, Peablossom Academy.
To register and for full details of the programme and sponsors, visit www.spvs-vpma-events.co.uk
BVA President Malcolm Morley said: “Judging this competition has been genuinely both extremely enjoyable and really difficult.
"The entries this year have absolutely surpassed expectations and the level of talent on display is amazing.
"However, the photographs we have chosen are all well worthy of being finalists.
"From photos that made us laugh out loud, to others that made some of us feel close to tears, they evoked a range of emotions, but we were also impressed by the quality of the images, the creativity of the photographers and the composition of the photos, as well as the stories behind the lens.
The finalists are:
Vets at work
All creatures great and small
Happy pets that make us smile
The winners will be announced at BVA Live at Birmingham’s NEC in May, where this year there is also an opportunity for BVA Live delegates to vote for their favourite image from the shortlist, with a new ‘People’s Choice’ winner being announced in the weeks following the event.
The aim of the study was to assess the efficacy and adverse effect profile of each individual AED by analysing all available data published and then evaluating how reliable it was.
The researchers gathered, screened and assessed all the information published in peer-reviewed journals and publications. The individual studies were then evaluated based on the quality of evidence, study design, study group sizes, subject enrolment quality and overall risk of bias, as well as the efficacy and safety outcome measures.
Lead-author, Marios Charalambous from Ghent University, said: "We recruited systematic methods to combine, compare and summarise the results of independent studies and, therefore, create more objective and reliable conclusions based on the current evidence. It was a time-consuming, demanding and challenging process, and we hope we provided the clinicians now with essential information which they can use for daily practice."
The researchers found that much of the evidence for the medical treatment of feline epilepsy was based on below-par reporting of efficacy and adverse effect, worse than what was formerly reported in dogs.
The lack of good quality evidence led authors to conclude that it would be: "...rather inaccurate to make definite statements on which one [AED] should be considered as a first or second choice in terms of both efficacy and safety profile. However, if clinicians focus on AED’s efficacy, phenobarbital can be used as first-choice monotherapy and if they focus on AED’s safety, imepitoin or levetiracetam can be used."
Holger Volk, Head of the Department Clinical Science and Services and Professor of Veterinary Neurology and Neurosurgery at the RVC, said: "Not only does this study offer a new perspective on the management of feline epilepsy, but also highlights the importance of the need for trials which provide high quality evidence in order to have more reliable and objective results about the efficacy and safety of the AEDs in feline epilepsy."
The study was published in BMC Veterinary Research (https://doi.org/10.1186/s12917-018-1386-3).
The RCVS has launched a new College honour, the RCVS Queen's Medal.
RCVS President Col Neil Smith said: "The Queen's Medal will be the most prestigious honour that the RCVS can bestow upon a veterinary surgeon and will be reserved for those whose distinguished careers and outstanding lifetime achievements deserve wider recognition."
The honour was created following a review of the RCVS honours system, which demonstrated the need for a new aspirational award.
The RCVS wrote to the Cabinet Office last year, together with letters of support from Peers and MPs, many of whom attended the reception, to request permission to name this new honour after Her Majesty the Queen.
Col Smith said: "We are honoured that Her Majesty has supported the proposal and allowed the College to name the award after her, and express our sincere thanks to those Parliamentarians who supported our endeavour."
The first RCVS Queen's Medal will be presented at RCVS Day in July 2014. The nomination form for the Queen's Medal can be found at www.rcvs.org.uk/Queensmedal.
"We would like to reassure vets, and through them dog owners, that we are constantly reviewing adverse event report data to ensure that the benefits of each UK licenced veterinary medicine product outweighs the risk posed by their potential side-effects.
There are a number of vaccines authorised in the UK containing either two (L2) or four (L4) strains of Leptospira. Based on the most recent periodic safety update report data received for each product, the incidence of adverse animal reactions for all L2 vaccine products combined is 0.015%; for L4 vaccine products this figure is 0.069%.
In other words, the VMD has received fewer than 2 adverse reactions for L2, and fewer than 7 for L4, for every 10,000 doses sold. This includes every suspected adverse event reported, even cases that were considered unclassifiable or were later found to be unrelated to the vaccine.
The overall incidence of suspected adverse reactions for both L2 and L4 vaccine products is therefore considered to be rare."
Under the protocol trial, the RCVS can launch private prosecutions against unqualified people practising veterinary surgery or using the title 'veterinary surgeon'.
The College says that where breaches of the Veterinary Surgeons Act cross over to other criminal offences, for example, fraud by false representation, they will be more properly dealt with by the relevant police force.
Local authority trading standards agencies will also deal with issues around, for example, misleading courses that purport to lead to registration with the RCVS but do not; concerns about dog grooming businesses and concerns about dog breeding establishments (other than where there is illegal practice of veterinary surgery by unqualified persons).
Eleanor Ferguson, RCVS Registrar and Director of Legal Services, said: “This protocol recognises that there are constraints on the time, resourcing, and budgets of both the police and public prosecutors which means that the pursuit of these breaches of the Veterinary Surgeons Act, both of which carry minor criminal penalties, is not necessarily a priority.
“While we are always willing to work with the police and other agencies to pursue such breaches, the protocol details how we can act independently where appropriate and ensure we are fulfilling our stated ambition to safeguard the interests of the public and animals, as well as the reputation of the professions, by ensuring that only those registered with us can carry out acts of veterinary surgery.
“We would like to manage expectations around this trial period as we will only be launching private prosecutions where they meet the criminal evidential standards of ‘beyond a reasonable doubt’ and it is judged to be in the public interest to do so.
"We will also be relying on members of the professions and the public to report breaches and provide sufficient evidence to us, as we have no statutory investigatory powers.”
The trial period will last for one year and the College has set aside £50,000 to pursue private prosecutions.
The trial will be overseen by the Disciplinary Committee/ Preliminary Investigation Committee Liaison Committee while decisions on whether to pursue private prosecutions will lie with the Registrar/ Director of Legal Services.
Suspected breaches of the Veterinary Surgeons Act can be reported to the RCVS Professional Conduct Department on breachvsa@rcvs.org.uk.
Merial Animal Health has launched Allevinix, a flunixin-based non-steroidal anti-inflammatory (NSAID) pain killer for cattle, pigs and horses.
Victoria Hudson, Product Manager for Merial Animal Health said: "We have positioned Allevinix as the flexible flunixin that meets your needs, because it offers flexibility in every area.
"It is the only flunixin licensed for both intramuscular and intravenous administration in cattle and we know that this will be very welcome for many vets and farmers. It can be used across cattle, pigs and horses, and it is the first injectable NSAID to come in a durable, non-breakable bottle."
Merial says Allevinix is fast-acting against inflammation, pain and fever, reaching peak plasma levels approximately 30 minutes after injection. It is available in 100ml and 250ml PET bottles and joins Ketofen as part of a range of NSAIDs available from Merial. It can also be used in conjunction with Merial's antimicrobial treatment for calf pneumonia - Zactran.
Victoria added: "We believe that vets will find this is a useful and innovative addition to the range of options that they have in terms of NSAIDs. Allevinix has a number of advantages over other flunixin products currently on the market."
Bayer Animal Health has announced that it will launch Seresto, a new POM-V collar for cats and dogs that kills fleas and repels and kills ticks for up to eight months, in March.
According to Bayer, Seresto is the first treatment to provide repellency against ticks in both cats and dogs, and represents the fruit of a multidisciplinary effort incorporating the company's research into insecticides, polymers and veterinary parasiticides. The end result is a polymer-based collar that transfers the active ingredients to the lipid layer, from where they are spread by the animal's neutral oils.
Bayer Animal Health group product manager, Caroline Braidwood, said: "Seresto is simple to use on both cats and dogs. And because it is long lasting, it offers pet owners an alternative to those struggling to maintain a monthly routine. Bayer believes in innovation and Seresto is an enhancement to our product portfolio that meets the needs and requirements of pet owners and vets alike in the treatment of ticks and fleas."
Seresto contains two active ingredients - imidacloprid for fast action against fleas and flumethrin, which repels and kills ticks.
Caroline added: "Thanks to Seresto's unique polymer structure the active ingredients are safely locked away in the collar's matrix, and are released directly from the collar surface into the lipid layer of the animal at just the dose needed, ensuring optimal protection is sustained for up to 8 months."
Bayer says that because of its repellent (anti-feeding) effect, Seresto reduces the risk of vector-borne disease transmission - a first for cats. The company also says that because the active ingredients are stored on the inside of the polymer, it doesn't matter if the pet is shampooed and the lipid layer stripped off - the active ingredients are quickly replenished by the collar.
Seresto is odour-free and has a safety release mechanism to prevent strangulation. It is available in three sizes, Seresto Cat for cats less than 8kgs, Seresto Small Dog for dogs up to 8kgs and Seresto Large Dogs, for dogs over 8kg.
For further information about Seresto, contact your Bayer territory manager or call 01635 563000.